NephroGenex begins public stock offering to raise $30 million

Bookrunners Canaccord and JMP expect to have $4.5 million greenshoe

By Marisa Wong

Madison, Wis., April 30 – NephroGenex, Inc. said it has begun an underwritten public offering of common stock and expects to raise up to $30 million.

NephroGenex also expects to grant the underwriters a 30-day option to purchase up to an additional $4.5 million of shares.

Canaccord Genuity Inc. and JMP Securities LLC are the joint bookrunners for the offering with Oppenheimer & Co. Inc. as lead manager and H.C. Wainwright & Co., LLC and Noble Life Science Partners as co-managers.

NephroGenex is a clinical-stage pharmaceutical company based in Raleigh, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.